Marvel Biosciences Corp
Capital Structure
•
in mil. unless spec.Working Capital
•
in mil. unless spec.Growth Rates
•
in mil. unless spec.Quarterly Revenue
•
in mil. unless spec.Quarterly Earnings Per Share
•
in mil. unless spec.Quarterly Dividends Per Share
•
in mil. unless spec.Company Description
- CEO
- Joseph Roderick Matheson
- Full Time Employees
- 5
- Sector
- Health technology
- Industry
- Pharmaceuticals: major
- Address
- 505 8th Avenue S.W. Calgary AB Canada T2P 1G2
- IPO Date
- Feb 28, 2019
- Website
- marvelbiotechnology.com
- Similar Companies
- Business
- Marvel Biosciences Corp. Marvel Biosciences Corp. (TSXV: MRVL), a Calgary, Alberta-based pre-clinical stage biotechnology company founded in 2021, develops synthetic chemical derivatives of off-patent drugs targeting the A2A adenosine receptor for neurological and non-neurological diseases; its lead product candidate, MB-204, a novel fluorinated derivative of Istradefylline originally approved for Parkinson's disease, demonstrates preclinical efficacy in Alzheimer's disease, depression, anxiety, autism, attention deficit hyperactivity disorder, Rett syndrome, Fragile X syndrome, and non-alcoholic steatohepatitis-associated liver fibrosis; additional pipeline assets include other A2A receptor inhibitors for cancer and related indications, supported by its wholly owned subsidiary Marvel Biotechnology Inc. The company operates primarily in Canada with global patent pursuits and targets large unmet needs in neurological diseases, cognitive and behavioral health, and neurodevelopmental genetic disorders through a drug redevelopment platform that reduces development costs, timelines, and risks compared to traditional biotech models. Recent developments include closing multiple tranches of non-brokered private placements raising up to $2.5 million in early 2025 for advancement toward Phase 1 clinical trials following completion of cGMP synthesis and toxicology studies; receipt of a notice of allowance for a composition-of-matter patent on MB-204 in China in January 2025, the first worldwide for this compound family; promising preclinical data from Rett syndrome studies in collaboration with the iBraiN Institute showing MB-204 outperforming trofinetide, prompting plans to file for U.S. FDA Orphan Drug Designation in March 2025; and selections for oral presentations at the 2025 IRSF Rett Syndrome Scientific Meeting and Alzheimer's Association International Conference.
Company News
Marvel Biosciences fait le point sur un placement privé pouvant atteindre 3 millions de dollars
Marvel Biosciences annonce la prolongation de la date limite de clôture du placement privé
Marvel Biosciences Announces Grant of Deferred Share Units
Marvell Technology (NASDAQ:MRVL) Shares Up 2.1% After Analyst Upgrade
Hager Investment Management Services LLC Has $1.53 Million Holdings in Marvell Technology, Inc. $MRVL
Chris Koopmans Sells 10,000 Shares of Marvell Technology (NASDAQ:MRVL) Stock
Mark Casper Sells 6,900 Shares of Marvell Technology (NASDAQ:MRVL) Stock
Marvel Biosciences Secures Funding to Develop Child-Friendly Liquid Formulation for Neurodevelopmental Disorders
Bourse de Toronto, Marvel Biosciences Corp., Perspective de la haute direction